Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by Sonny7on Jul 14, 2013 5:09am
148 Views
Post# 21606345

RE:Board

RE:BoardTrue enough. Many people think that CEO is redundant, or maybe a natural target for shareholders frustrations. If RVX is to succeed an any way then we may have to place our shares into our last will and testaments for the beneficiary of our choice. My feeling is that the drug has true value as a preventative drug for heart disease at the very least. Maybe Dr Wong and company may be robbed of the Nobel Prize for their stellar efforts. Look what happened to this Doctor as shown in the link below. If you have never heard of him then look at the documentary starting with part 1 and then go on to part 2.

Make some popcorn, put your feet up and watch the documentary. It's well worth the time to view both parts. It should give you a lot to think about and especially if you experienced the AHA fiasco with RVX after the ASSERT trials.

It's interesting that the last two breakthrough drugs have been insulin and then penicillin.

https://www.burzynskimovie.com/
Bullboard Posts